Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A 1chieve study

Primary Care Diabetes

Volumn 8, Issue 2, 2014, Pages 111-117

  Dieuzeide, Guillermo ^a   Chuang, Lee Ming ^b   Almaghamsi, Abdulrahman ^c   Zilov, Alexey ^d   Chen, Jian Wen ^e   Lavalle González, Fernando J ^f  

^a Centro de Atención Integral en Diabetes Endocrinología Y Metabolismo   (Argentina)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e Novo Nordisk FemCare AG   (Switzerland)

^f HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Basal bolus insulin regimen; Biphasic insulin aspart; Type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; BIPHASIC INSULIN; GLARGINE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; LONG ACTING INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; AFRICA; AGED; ASIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SUBSTITUTION; INJECTION; METABOLISM; MIDDLE AGED; MIDDLE EAST; MULTICENTER STUDY; RUSSIAN FEDERATION; SOUTH AND CENTRAL AMERICA; TIME;

ADULT; AFRICA, NORTHERN; AGED; ASIA; BIOLOGICAL MARKERS; BIPHASIC INSULINS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN ASPART; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; LATIN AMERICA; MALE; MIDDLE AGED; MIDDLE EAST; QUALITY OF LIFE; RUSSIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901806502     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2013.07.005     Document Type: Article

References (24)

1. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial Diabetes 45 1996 1289 1298
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
3. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
4. R.J. Ligthelm, U. Mouritzen, and H. Lynggaard et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes Experimental and Clinical Endocrinology and Diabetes 114 2006 511 519
5. M. Hamaty Insulin treatment for type 2 diabetes: when to start, which to use Cleveland Clinic Journal of Medicine 78 2011 332 342
6. A.J. Garber, J. Wahlen, and T. Wahl et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) Diabetes, Obesity and Metabolism 8 2006 58 66
7. P. Raskin, E. Allen, and P. Hollander et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs Diabetes Care 28 2005 260 265
8. A. Liebl, R. Prager, and K. Binz et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial Diabetes, Obesity and Metabolism 11 2009 45 52
9. 1chieve study Diabetes Research and Clinical Practice 94 2011 352 363
10. 1chieve observational study Diabetes Research and Clinical Practice 94 2011 364 370
11. International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices (GPP). Revision 2 April 2007
12. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects 2008 Available at: http://www.riip-influenza.org/wp-content/uploads/2011/08/Helsinki-2008-EN.pdf. Last accessed (08.11.2011)
13. R.R. Holman, A.J. Farmer, and M.J. Davies et al. Three-year efficacy of complex insulin regimens in type 2 diabetes The New England Journal of Medicine 361 2009 1736 1747
14. A. Zambanini, R.B. Newson, M. Maisey, and M.D. Feher Injection related anxiety in insulin-treated diabetes Diabetes Research and Clinical Practice 46 1999 239 246
15. A.B. Hauber, F.R. Johnson, L. Sauriol, and B. Lescrauwaet Risking health to avoid injections: preferences of Canadians with type 2 diabetes Diabetes Care 28 2005 2243 2245
16. L.A. Donnelly, A.D. Morris, and J.M. Evans Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes The Quarterly Journal of Medicine 100 2007 345 350
17. A.D. Mooradian, M. Bernbaum, and S.G. Albert Narrative review: a rational approach to starting insulin therapy Annals of Internal Medicine 145 2006 125 134
18. A. Vaag, and S.S. Lund Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues European Journal of Endocrinology 166 2012 159 170
19. M. Peyrot, R.R. Rubin, D.F. Kruger, and L.B. Travis Correlates of insulin injection omission Diabetes Care 33 2010 240 245
20. M. Peyrot, R.R. Rubin, and T. Lauritzen et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 28 2005 2673 2679
21. R.J. Ligthelm Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice Primary Care Diabetes 3 2009 97 102
22. A.G. Unnikrishnan, J. Tibaldi, and M. Hadley-Brown et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement International Journal of Clinical Practice 63 2009 1571 1577
23. W.J. Valentine, R.F. Pollock, J. Plun-Favreau, and J. White Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes Current Medical Research and Opinion 26 2010 1399 1412
24. L. Gero, A. Gyimesi, T. Hidvegi, and I. Janosi Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart Orvosi Hetilap 150 2009 1637 1647